Imugene Ltd (ASX: IMU) Share Price and News

Ms Chong has over 23 years experience in clinical and department development in oncology. Previously, she was serving at oncology clinical development company, Genentech (a member of the Roche family), as a Senior Clinical Program Lead at the head office in San Francisco. She is also a director of Cure Brain Cancer Foundation (non-profit organisation), since April 2020.

Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a focus on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. He is also a former director of Scopus BioPharma Inc.

Dr Russell has over 25 years experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell is a director of Enanta Pharmaceuticals, since 22 November 2016 and former director of Scopus BioPharma Inc, until March 2021. Dr Russell is also a member of Risk Committee.

Dr Eckstein has more than 20 years venture capital experience in the biopharmaceutical industry and 10 years operational experience in drug discovery and development. He is a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at TVM Capital. Dr Eckstein is also a member of Risk Committee.

Dr Dupont is an industry and academic drug development expert, specialising in oncology and other therapeutic areas, with more than 20 years of experience. He has made contributions to the development and approval of ten oncology drugs and has orchestrated development programs for numerous drugs. Dr Dupont is currently the Global Head of Research and Development at NASDAQ-listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversees all research and development including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous pre-clinical programs. He also oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the Board of Directors. Prior to Atara, Dr Dupont spent more than six years in various roles at Genentech/Hoffman-La Roche including as Vice President, Global Head of Breast and GYN Cancer Development, in addition to a further five years at Oncomed Pharmaceuticals as Senior Vice President and Chief Medical Officer. Dr Dupont is currently an Independent Director at Apexigen (NASDAQ: APGN) and a Scientific Advisory Board Member at AMBRX (NASDAQ: AMAM). He has been published 48 times in peer-reviewed journals and has established relationships with global clinical and research oncologists, collaborative groups, industry and investors.

Ms Drapkin has 25 years of experience in the biotechnology and pharmaceutical sectors, Ms Drapkin has a background in finance, capital raising, and strategic financial planning. She held the position of CFO and Treasurer at Jounce Therapeutics, Inc. from 2015 until its acquisition in May 2023, having played a role in the companys growth and financing since its inception. Before joining Jounce, Ms Drapkin managed a financial consulting firm and served as interim CFO for various early-stage biotech companies, including Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals, Avila Therapeutics, Inc., and Voyager Therapeutics, Inc. Prior to that, she held CFO positions at EPIX Pharmaceuticals and have experience at Millennium Pharmaceuticals. Ms Drapkin also currently serves as the audit committee chair and compensation committee member on Acumen Pharmaceuticals board (NASDAQ: ABOS). Previously, she served on Proteostasis Therapeutics board (NASDAQ: PTI) from 2019 to 2020 and continued on Yumanity Therapeutics board (NASDAQ: YMTX) following its merger with PTI in December 2020 until December 2022. In PTI and Yumanity, she chaired the audit committee and participated in the governance and compensation committees. Ms. Drapkin also served on transaction committees for both companies.

-

-